The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Results from the randomized Phase III DaunoDouble trial
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, comments on the results from the Phase III DaunoDouble trial (NCT02140242), which sought to answer two key questions in newly diagnosed acute myeloid leukemia (AML). The trial demonstrated that 60mg of daunorubicin is the optimal dose at first induction, as there was no difference in early responses, complete response (CR) rates, or overall survival (OS) between patients receiving 60mg or 90mg. Moreover, in those with good responses to the first cycle of induction, a second induction is not necessary, as it provided no significant benefit in CR or OS rates. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy, Honoraria; Amgen: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Servier: Consultancy; Jazz: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria.
